Published in final edited form as:

Int J Cancer. 2021 January 15; 148(2): 307–319. doi:10.1002/ijc.33206.

Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer

A full list of authors and affiliations appears at the end of the article.

These authors contributed equally to this work.

Abstract

Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two-sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low-density lipoprotein [LDL] and high-density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels ($P < 5 \times 10^{-8}$) were identified as instrumental variables, and assessed using genome-wide association study data from the Endometrial Cancer Association Consortium (12 906 cases and 108 979 controls) and the Global Lipids Genetic Consortium ($n = 188\,578$). Mendelian randomization analyses found genetically raised LDL cholesterol levels to be associated with lower risks of endometrial cancer of all histologies combined, and of endometrioid and non-endometrioid subtypes. Conversely, higher genetically predicted HDL cholesterol levels were associated with increased risk of non-endometrioid endometrial cancer. After accounting for the potential confounding role of obesity (as measured by genetic variants associated with body mass index), the association between genetically predicted increased LDL cholesterol levels and lower endometrial cancer risk remained significant, especially for non-endometrioid endometrial cancer. There was no evidence to support a role for triglycerides in endometrial cancer development. Our study supports a role for LDL and HDL cholesterol in the development of non-endometrioid endometrial cancer. Further studies are required to understand the mechanisms underlying these findings.

Correspondence Tracy A. O'Mara, PhD, Molecular Cancer Epidemiology Group, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane QLD Australia 4006. tracy.omara@qimrberghofer.edu.au.

CONFLICT OF INTEREST

Peter A. Fasching reports personal fees from Novartis, grants from Biontech, personal fees from Roche, personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from Astra Zeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre, personal fees from Seattle Genetics, during the conduct of the study. Deborah J. Thompson is an employee of Genomics plc. The research described in this article was completed before her employment at Genomics plc. All other authors declare no potential conflicts of interest.

ETHICS APPROVAL

This work used published summary-level GWAS meta-analysis results, and thus ethical approval was not required.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

Keywords

endometrial cancer risk; HDL cholesterol; LDL cholesterol; Mendelian randomization; triglycerides

1 | INTRODUCTION

Endometrial cancer primarily affects postmenopausal women and approximately 382 000 cases were diagnosed in 2018.¹ Risk factors for endometrial cancer include: family history of endometrial cancer²; increasing age, obesity (eg, high body mass index [BMI] and low physical activity), unopposed estrogen exposure (eg, early age of menarche, late age of menopause, nulliparity, hormone replacement therapy without progesterone and tamoxifen use)^{3,4}; and fasting insulin levels.⁵ Despite the advances that have been made in identifying endometrial cancer risk factors, endometrial cancer incidence is still rising.⁶

Obesity is the strongest risk factor for endometrial cancer, with up to ~60% increased risk per 5 kg/m² higher BMI.⁷ However, the mechanism(s) by which higher BMI predisposes to endometrial cancer is (are) not well understood. Adipose tissue is an important site for the synthesis of estrogen (another endometrial cancer risk factor), especially after menopause, via the conversion of androgens to estrogens by aromatase.⁸ BMI also has a complex relationship with blood lipid levels, with Mendelian randomization analyses finding bidirectional associations between levels of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides and BMI.⁹ Moreover, cholesterol has been suggested to play a role in cancer development by inducing chronic inflammation.¹⁰⁻¹²

Blood lipid levels have been suggested to contribute to pathogenesis of endometrial cancer. As hypertriglyceridemia and hyper-LDL cholesterolemia are common in endometrial cancer survivors,¹³ case-control studies assessing changes in blood lipid levels at/after endometrial cancer diagnosis are susceptible to reverse causation bias.¹⁴⁻¹⁶ Observational studies conducted to examine the association between prediagnostic blood lipid levels and endometrial cancer risk¹⁷⁻²³ reported significant positive associations from only three studies assessing blood triglycerides level and endometrial cancer risk.^{18,19,23} Inconsistent findings from observational studies could be due to small study populations^{17,20} and a lack of adjustment for obesity.^{18,22} Furthermore, the use of nonfasting blood lipid levels in observational studies could also contribute to the variation in published findings.^{17-19,21-23} Several studies have assessed the association of blood lipids with endometrial cancer by subtype,^{15,19,21,23} but only one has assessed the prediagnostic blood lipid levels. Our study reported increased triglycerides levels to be associated with the risk of both Type 1 and 2 endometrial cancers.²³ However, our study did not adjust for obesity, and used nonfasting blood lipid levels. As obesity and blood lipid levels are interrelated,⁹ it has been difficult for observational studies to disentangle the effects of blood lipid levels on endometrial cancer risk. Thus, the relationship between blood lipids and endometrial cancer remains unclear from the existing evidence.

Mendelian randomization is an instrumental variable analysis that assesses the effects of exposures using genetic predictors as instrumental variables.²⁴ Mendelian randomization

uses the principle that the alleles of genetic variants which predict higher levels of an exposure of interest are naturally randomized to individuals at meiosis, a process somewhat comparable to the random assignment of participants to an exposure in a randomized controlled trial. Thus, associations between genetic variants and the outcome (and hence between the exposure and the outcome) will not be vulnerable to reverse causation because disease develops after meiosis. Provided that the selected genetic variants are associated with the outcome only via their effects on the exposure of interest (ie, not via pleiotropic effects on other traits which could independently alter disease risk), effect estimates generated by Mendelian randomization analyses should also be less vulnerable to the influence of confounders.²⁴

In the current study, we employed a two-sample Mendelian randomization framework to assess the relationships between levels of three blood lipids (LDL and HDL cholesterol, and triglycerides) and the risk of endometrial cancer using genome-wide association study (GWAS) data from the Endometrial Cancer Association Consortium (ECAC) and Global Lipids Genetic Consortium (GLGC).

2 | MATERIALS AND METHODS

2.1 | GWAS datasets

In our study, we assessed three major blood lipids: LDL and HDL cholesterol, and triglycerides. Summary statistics from GWAS for the three blood lipids in 188 577 individuals of predominantly European ancestry were obtained from the Global Lipid Genetics Consortium²⁵ (<http://csg.sph.umich.edu/willer/public/lipids2013/>). A detailed description of the GLGC study has been previously published.²⁵ Briefly, blood lipid levels were measured more than 8 hours after fasting in most GLGC studies. For each genetic variant association with blood lipid levels, association estimates were expressed in SD per copy of the effect allele.

Endometrial cancer risk estimates were obtained from the largest published meta-GWAS to date, conducted by ECAC in 12 906 endometrial cancer cases and 108 979 controls, all of European ancestry.²⁶ In a secondary analysis, we investigated relationships between the three blood lipids and endometrial cancer subtypes using ECAC meta-GWAS results restricted to cases with either endometrioid histology (8758 cases), or non-endometrioid histology (1230 cases).²⁶ Histological subtypes of endometrial cancer were confirmed based on pathology reports, and detailed study descriptions have previously been reported.^{26,27} The association estimates were expressed in log(OR) per copy of the effect allele.

2.2 | Instrumental variable selection

Independent, genome-wide significant genetic variants ($r^2 < 0.05$, $P < 5 \times 10^{-8}$) that were associated with each type of blood lipid were chosen as instrumental variables. Genetic variants with ambiguous strand codification (A/T or C/G) and minor allele frequency more than 0.42 were removed. We compared the allele frequencies between the GLGC and ECAC datasets, and a UKB10K reference panel (a random subset of 10 000 unrelated participants

from UK Biobank cohort; <https://www.ukbiobank.ac.uk/>), and genetic variants with a large allele frequency difference (>0.2) were also excluded.

2.3 | Bidirectional Mendelian randomization analysis

We employed bidirectional Generalized Summary-data based Mendelian Randomization (GSMR) analysis²⁸ to explore the relationship between the three blood lipids and endometrial cancer. As Mendelian randomization estimates may be confounded by including pleiotropic variants, we implemented the built-in Heterogeneity in Dependent Instruments (HEIDI) outlier test²⁸ with a P -value threshold of .01 to detect and filter heterogeneous variants that are likely pleiotropic. Remaining variants not excluded by HEIDI outlier test were used as nonpleiotropic instrumental variables.

Results with a Bonferroni-adjusted $P < .05/3 = .017$, correcting for the three blood lipid traits tested, were considered statistically significant. When blood lipid levels were treated as the exposure trait, the resulting effect estimates were expressed as odds ratios (OR) and 95% confidence intervals (CIs) for endometrial cancer risk per SD increment in genetically predicted blood lipid level. When endometrial cancer risk was treated as the exposure trait, the resulting estimates represent the SD change for blood lipid level per SD increase in the genetic liability to endometrial cancer. Analyses were performed using default settings in the GSMR extension in GCTA (version 1.92),²⁸ using the UKB10K reference panel to estimate linkage disequilibrium between variants. For comparison, we also performed inverse variance weighted (IVW) and MR-Egger regression Mendelian randomization analyses using MR-Base.²⁹

2.4 | Conditional Mendelian randomization analysis

Since obesity could affect associations between blood lipid levels and endometrial cancer,⁹ we additionally performed conditional Mendelian randomization analysis. GWAS summary statistics for the lipid of interest were conditioned for the effect of genetically predicted BMI using results from the largest GWAS of BMI to date.³⁰ Conditional analyses were performed using multi-trait-based conditional and joint analysis in the GCTA software package (version 1.92)²⁸ and adjusted estimates were then reanalyzed by GSMR.

3 | RESULTS

After removal of potential pleiotropic variants, 140 LDL cholesterol, 163 HDL cholesterol and 104 triglyceride independent genome-wide significant variants were considered as instrumental variables (Supplementary Tables S1-S3). These instrumental variables were used by GSMR to estimate the effect of blood lipids on endometrial cancer risk of all histologies combined (results presented in Table 1 and Figure 1). GSMR analysis indicated that genetically raised LDL cholesterol levels were associated with reduced risk of all endometrial cancer histologies combined (OR per SD increase in LDL cholesterol level = 0.88; 95% CI = 0.83-0.93; $P = 7.26 \times 10^{-6}$). Consistent with the divergent roles of LDL and HDL cholesterol,³¹ GSMR analysis provided evidence that increased HDL cholesterol levels may be associated with increased risk of all endometrial cancer histologies combined (OR = 1.07; 95% CI = 1.00-1.14; $P = .037$). Secondary analysis assessing the relationships between

blood lipid levels and endometrial cancer subtypes found genetically predicted higher LDL cholesterol levels were associated with lower risk of both endometrioid and non-endometrioid endometrial cancer (Table 1). Conversely, genetically predicted higher HDL cholesterol levels showed suggestive evidence of association with higher risk of non-endometrioid endometrial cancer only (Table 1). No significant effects were observed for triglycerides on endometrial cancer overall, or its subtypes (Table 1). Bidirectional GSMR analysis provided evidence for a unidirectional association, for example, genetically elevated LDL cholesterol level may affect endometrial cancer risk, while genetic liability to endometrial cancer does not appear to affect LDL cholesterol levels (Table 2).

To reduce the influence of obesity on the associations between blood lipid levels and endometrial cancer risk, we performed Mendelian randomization analysis conditioning on genetically predicted BMI. Results are presented in Table 3 and Supplementary Figure S1. After controlling for the influence of genetically predicted BMI, the association between genetically predicted LDL cholesterol levels and risk of all histologies combined and non-endometrioid endometrial cancer remained; whereas, the effect of LDL cholesterol level on endometrioid endometrial cancer risk was attenuated and no longer significant (OR = 0.93, 95% CI = 0.87-1.01; $P = 0.07$). Conditioning on genetically predicted BMI had minimal impact on the risk estimates for HDL and endometrial cancer, but associations did not pass the Bonferroni-correction threshold, reflecting the decreased power for these analyses.

Results from IVW and MR-Egger analyses were consistent with our GSMR results (Supplementary Tables S4 and S5). None of the MR-Egger intercepts were significantly different from zero ($P > .05$), except for the relationship between genetically predicted HDL cholesterol and non-endometrioid endometrial cancer, suggesting pleiotropy may have biased IVW results of HDL cholesterol and non-endometrioid endometrial cancer. However, the MR-Egger regression slope of HDL cholesterol and non-endometrioid endometrial cancer remained statistically significant after accounting for potential pleiotropy, supporting a relationship between HDL cholesterol and endometrial cancer risk (Supplementary Tables S4 and S5).

4 | DISCUSSION

To the best of our knowledge, this is the first Mendelian randomization study to assess the effects of genetically predicted blood lipid levels on endometrial cancer risk. While genetically increased LDL cholesterol had a protective effect on endometrial cancer, especially non-endometrioid endometrial cancer, results suggest that genetically increased HDL cholesterol may have an adverse effect on non-endometrioid endometrial cancer risk. The opposing findings for LDL and HDL cholesterol are consistent with their opposing roles. For example, LDL delivers cholesterol to peripheral tissues, whereas HDL removes cholesterol from these tissues and transports it to the liver.³¹ We found no evidence of a causal link between triglycerides and endometrial cancer, in contrast to three observational studies that have reported positive associations.^{18,19,23} However, as previously noted, none of these studies assessed fasting blood triglycerides and one did not control for the effect of obesity.¹⁸

Mendelian randomization analysis has previously illustrated the complex interrelationship between BMI and blood lipid levels.⁹ We therefore performed conditional Mendelian randomization analysis to investigate the influence of genetically predicted BMI on associations between LDL/HDL cholesterol and endometrial cancer risk. Comparison of the LDL/HDL cholesterol association estimates, before and after adjusting for genetically predicted BMI, did not support a role for BMI in the associations with endometrial cancer of non-endometrioid and combined histologies. In contrast, the LDL cholesterol association with endometrioid endometrial cancer was weaker with wider CIs after including genetically predicted BMI as covariate. While a modest protective effect of LDL cholesterol for the endometrioid subtype of endometrial cancer cannot be excluded, this finding indicated that LDL cholesterol is likely to lie in the same causal pathway as obesity, a hypothesis consistent with results from previous genetic studies. Indeed, somewhat surprisingly, previous Mendelian randomization analyses have demonstrated a bidirectional relationship between LDL cholesterol and BMI with one study reporting that increased LDL cholesterol levels were associated with reduced BMI⁹ and, another reporting that increased BMI was associated with reduced LDL cholesterol levels.³² Using Mendelian randomization analyses, we have previously found increased BMI to be associated with increased endometrioid endometrial cancer risk.^{26,33} Measured LDL cholesterol levels have also been found to diminish with increasing BMI in overweight individuals³⁴; whereas, in the same study, LDL cholesterol levels were only positively correlated with BMI in lean individuals. These findings indicate that the inverse relationship between LDL cholesterol and endometrioid endometrial cancer, a disease primarily affecting overweight individuals,³³ may be related to high BMI. Thus, we hypothesize that obesity is likely to be the mediator of the effect of LDL cholesterol on endometrioid endometrial cancer risk (ie, $\uparrow\text{LDL} \rightarrow \downarrow\text{BMI} \rightarrow \downarrow\text{Endometrioid Endometrial Cancer risk}$) (Figure 2). Moreover, as obesity is a stronger risk factor for endometrioid than for non-endometrioid endometrial cancer,²⁶ it is perhaps not surprising that after adjusting for genetically predicted BMI we only observed an attenuation of the effect of LDL cholesterol on endometrioid endometrial cancer risk.

It is intriguing that our results indicated that, independent of obesity, decreased LDL cholesterol level is inversely associated with risk of non-endometrioid endometrial cancer. While both endometrioid and non-endometrioid endometrial cancer share many other risk factors,³⁵ recent Mendelian randomization analyses have found that obesity and age at menarche are risk factors of endometrioid endometrial cancer only.²⁶ Given the rare nature of non-endometrioid histologies (~10% of all endometrial cancer cases), the tumorigenic mechanisms for these histological subtypes remain largely unknown.^{35,36} Thus, further studies are required to explore how higher LDL cholesterol levels could protect against non-endometrioid endometrial cancer development.

As shown in Table 1, the association between HDL cholesterol and endometrial cancer appears to be largely driven by the non-endometrioid histological subtype. Despite not passing a Bonferroni statistical significance threshold, there was no substantial change in the association estimate before and after conditioning on BMI, suggesting HDL cholesterol may also affect non-endometrioid endometrial cancer risk independently of obesity. The wide CIs suggest that future studies with more non-endometrioid endometrial cancer cases are required to further dissect any effect.

The conflicting findings regarding the relationships between blood lipids and endometrial cancer risk in observational studies may be due to small sample sizes, varying timing of blood collection (eg, fasting or nonfasting, and pre- or post-endometrial cancer diagnosis), and varying control for confounding factors. Findings presented in the current study, through the application of bidirectional Mendelian randomization which is less vulnerable to reverse causation and confounding, have helped to clarify the effects of blood lipids on endometrial cancer risk. Consistent with our findings, other Mendelian randomization studies have observed a positive association between HDL cholesterol and breast cancer risk,³⁷⁻³⁹ and an inverse association between LDL cholesterol and lung cancer risk.⁴⁰ Similarly, a time-to-event Mendelian randomization using data from five longitudinal cohort studies reported increased LDL cholesterol level to be associated with reduced cancer risk (all reported cancer types combined).⁴¹

The potential mechanisms underlying the effects of decreased LDL and increased HDL cholesterol on cancer risk are unclear as reports of the effects of cholesterol in the literature are conflicting. However, oxidized LDL has been shown to be cytotoxic to cancer cells⁴² and can inhibit angiogenesis,^{43,44} a key oncogenic process. Furthermore, given the prevalence of Type 2 diabetes in endometrial cancer patients, it is noteworthy that HDL cholesterol from diabetic patients, which is often glycosylated or oxidized, promotes cancer cell proliferation, migration and invasion in vitro⁴⁵ and metastasis in vivo.⁴⁶

The validity of Mendelian randomization analysis lies upon the satisfaction of the assumption that the effect of the instrumental variables on the outcome is only mediated through their influence on the measured exposure (ie, no horizontal pleiotropy). One caveat of our study is that we do not have complete information of all confounding factors, and thus we did not have the ability to evaluate or adjust for unmeasured confounders in the Mendelian randomization analysis. Despite the lack of information on confounding factors, we also performed several Mendelian randomization analyses that are more robust to unmeasured confounding (ie, HEIDI test in GSMR analysis removes variants which show evidence of horizontal pleiotropy, and MR-Egger analysis allows instrumental variables to be pleiotropic). We observed consistent results across different Mendelian randomization analyses, and this suggests that residual confounding may have negligible impact on our results. The two-sample Mendelian randomization framework allowed us to incorporate data from two very large independent GWAS datasets to bolster power and yield more precise association estimates. However, we were restricted to summary-level GWAS data, and thus, could not perform more refined analyses (eg, stratification analysis by BMI).

This Mendelian randomization study provides evidence that increased LDL cholesterol and decreased HDL cholesterol, independent of obesity, may reduce the risk of endometrial cancer. This effect was particularly apparent for the non-endometrioid endometrial cancer subtype, which typically has a more aggressive phenotype and results in poorer prognosis. Although further work is required to elucidate the biological rationale underlying this association, these results suggest low LDL cholesterol levels and high HDL cholesterol levels should be considered as potential risk factors for endometrial cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Pik-Fang Kho^{1,2}, Frederic Amant³, Daniela Annibali³, Katie Ashton^{4,5,6}, John Attia^{4,7}, Paul L. Auer^{8,9}, Matthias W. Beckmann¹⁰, Amanda Black¹¹, Louise Brinton¹¹, Daniel D. Buchanan^{12,13,14,15}, Stephen J. Chanock¹⁶, Chu Chen¹⁷, Maxine M. Chen¹⁸, Timothy H. T. Cheng¹⁹, Linda S. Cook^{20,21}, Marta Crous-Bous^{18,22}, Kamila Czene²³, Immaculata De Vivo^{18,22}, Joe Dennis²⁴, Thilo Dörk²⁵, Sean C. Dowdy²⁶, Alison M. Dunning²⁷, Matthias Dürst²⁸, Douglas F. Easton^{24,27}, Arif B. Ekici²⁹, Peter A. Fasching^{10,30}, Brooke L. Fridley³¹, Christine M. Friedenreich²¹, Montserrat Garcia-Closas¹⁶, Mia M. Gaudet³², Graham G. Giles^{13,33,34}, Ellen L. Goode³⁵, Maggie Gorman¹⁹, Christopher A. Haiman³⁶, Per Hall^{23,37}, Susan E. Hankinson^{22,38}, Alexander Hein¹⁰, Peter Hillemanns²⁵, Shirley Hodgson³⁹, Erling A. Hoivik^{40,41}, Elizabeth G. Holliday^{4,7}, David J. Hunter^{18,42,43}, Angela Jones¹⁹, Peter Kraft^{18,42}, Camilla Krakstad^{40,41}, Diether Lambrechts^{44,45}, Loic Le Marchand⁴⁶, Xiaolin Liang⁴⁷, Annika Lindblom^{48,49}, Jolanta Lissowska⁵⁰, Jirong Long⁵¹, Lingeng Lu⁵², Anthony M. Magliocco⁵³, Lynn Martin⁵⁴, Mark McEvoy⁷, Roger L. Milne^{13,33,34}, Miriam Mints⁵⁵, Rami Nassir⁵⁶, Geoffrey Otton⁵⁷, Claire Palles¹⁹, Loreall Pooler³⁶, Tony Proietto⁵⁷, Timothy R. Rebbeck^{58,59}, Stefan P. Renner⁶⁰, Harvey A. Risch⁵², Matthias Rübner⁶⁰, Ingo Runnebaum²⁸, Carlotta Sacerdote^{61,62}, Gloria E. Sarto⁶³, Fredrick Schumacher⁶⁴, Rodney J. Scott^{4,6,65}, V. Wendy Setiawan³⁶, Mitul Shah²⁷, Xin Sheng³⁶, Xiao-Ou Shu⁵¹, Melissa C. Southey^{12,33,34}, Emma Tham^{48,66}, Ian Tomlinson^{19,54}, Jone Trovik^{40,41}, Constance Turman¹⁸, Jonathan P. Tyrer²⁷, David Van Den Berg³⁶, Zhaoming Wang¹¹, Nicolas Wentzensen¹¹, Lucy Xia³⁶, Yong-Bing Xiang⁶⁷, Hannah P. Yang¹¹, Herbert Yu⁴⁶, Wei Zheng⁵¹, Penelope M. Webb⁶⁸, Deborah J. Thompson²⁴, Amanda B. Spurdle¹, Dylan M. Glubb^{#1}, Tracy A. O'Mara^{#1}

Affiliations

¹Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia ²School of Biomedical Science, Queensland University of Technology, Brisbane, Queensland, Australia ³Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals KU Leuven, University of Leuven, Leuven, Belgium ⁴Hunter Medical Research Institute, John Hunter Hospital, Newcastle, New South Wales, Australia ⁵Centre for Information Based Medicine, University of Newcastle, Callaghan, New South Wales, Australia ⁶Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, Callaghan, New South Wales, Australia ⁷Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia ⁸Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington ⁹Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin ¹⁰Department of Gynecology and Obstetrics,

Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany ¹¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland ¹²Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia ¹³Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia ¹⁴Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Victoria, Australia ¹⁵University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia ¹⁶Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland ¹⁷Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington ¹⁸Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts ¹⁹Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK ²⁰University of New Mexico Health Sciences Center, Albuquerque, New Mexico ²¹Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Alberta, Canada ²²Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts ²³Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden ²⁴Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK ²⁵Gynaecology Research Unit, Hannover Medical School, Hannover, Germany ²⁶Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, Minnesota ²⁷Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK ²⁸Department of Gynaecology, Jena University Hospital - Friedrich Schiller University, Jena, Germany ²⁹Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany ³⁰David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California ³¹Department of Biostatistics, Kansas University Medical Center, Kansas City, Kansas ³²Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia ³³Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia ³⁴Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia ³⁵Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota ³⁶Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California ³⁷Department of Oncology, Södersjukhuset, Stockholm, Sweden ³⁸Department of Biostatistics & Epidemiology, University of Massachusetts, Amherst, Amherst, Massachusetts ³⁹Department of Clinical Genetics, St George's, University of London, London, UK ⁴⁰Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen,

Bergen, Norway ⁴¹Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway ⁴²Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts ⁴³Nuffield Department of Population Health, University of Oxford, Oxford, UK ⁴⁴VIB Center for Cancer Biology, Leuven, Belgium ⁴⁵Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium ⁴⁶Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii ⁴⁷Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York ⁴⁸Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden ⁴⁹Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden ⁵⁰Department of Cancer Epidemiology and Prevention, M. Skłodowska-Curie Cancer Center, Oncology Institute, Warsaw, Poland ⁵¹Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee ⁵²Chronic Disease Epidemiology, Yale School of Medicine, New Haven, Connecticut ⁵³Department of Anatomic Pathology, Moffitt Cancer Center & Research Institute, Tampa, Florida ⁵⁴Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK ⁵⁵Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden ⁵⁶Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, California ⁵⁷School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia ⁵⁸Harvard T.H. Chan School of Public Health, Boston, Massachusetts ⁵⁹Dana-Farber Cancer Institute, Boston, Massachusetts ⁶⁰Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany ⁶¹Center for Cancer Prevention (CPO-Piemonte), Turin, Italy ⁶²Human Genetics Foundation (HuGeF), Turin, Italy ⁶³Department of Obstetrics and Gynecology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin ⁶⁴Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio ⁶⁵Division of Molecular Medicine, Pathology North, John Hunter Hospital, Newcastle, New South Wales, Australia ⁶⁶Clinical Genetics, Karolinska Institutet, Stockholm, Sweden ⁶⁷State Key Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China ⁶⁸Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

ACKNOWLEDGMENTS

This work was conducted using the UK Biobank Resource (application number 25331). The authors thank the many individuals who participated in the Endometrial Cancer Association Consortium studies and the numerous institutions and their staff who supported recruitment. The iCOGS and OncoArray endometrial cancer analysis were supported by National Health and Medical Research Council (NHMRC) project grants (ID#1031333 and ID#1109286). Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/

A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. OncoArray genotyping of ECAC cases was performed with the generous assistance of the Ovarian Cancer Association Consortium (OCAC). We particularly thank the efforts of Cathy Phelan. The OCAC OncoArray genotyping project was funded through grants from the US National Institutes of Health (CA1X01HG007491-01, U19-CA148112, R01-CA149429 and R01-CA058598), Canadian Institutes of Health Research (MOP-86727) and the Ovarian Cancer Research Fund. CIDR genotyping for the Oncoarray was conducted under contract 268201200008I. OncoArray genotyping of the BCAC controls was funded by Genome Canada Grant GPH-129344, NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563. Pik-Fang Kho is supported by an Australian Government Research Training Program PhD Scholarship and QIMR Berghofer Postgraduate Top-Up Scholarship. Tracy A. O'Mara is supported by an NHMRC Early Career Fellowship (APP1111246) and Amanda B. Spurdle is supported by an NHMRC Senior Research Fellowship (APP1061779).

Stage 1 and Stage 2 case genotyping was supported by the NHMRC (ID#552402, ID#1031333). Control data were generated by the Wellcome Trust Case Control Consortium (WTCCC), and a full list of the investigators who contributed to the generation of the data is available from the WTCCC website. We acknowledge the use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02; funding for this project was provided by the Wellcome Trust under award 085475. NSECG was supported by the EU FP7 CHIBCHA grant, Wellcome Trust Centre for Human Genetics Core Grant 090532/Z/09Z, and CORGI was funded by Cancer Research UK. We thank Nick Martin, Dale Nyholt and Anjali Henders for access to GWAS data from QIMR Controls. Recruitment of the QIMR controls was supported by the NHMRC. The University of Newcastle, the Gladys M Brawn Senior Research Fellowship scheme, The Vincent Fairfax Family Foundation, the Hunter Medical Research Institute and the Hunter Area Pathology Service all contributed towards the costs of establishing the Hunter Community Study. The WHI program is funded by the National Heart, Lung, and Blood Institute, the US National Institutes of Health and the US Department of Health and Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C). This work was also funded by NCI U19 CA148065-01. This research has been conducted using the UK Biobank Resource under applications 5122 and 9797.

ANECs recruitment was supported by project grants from the NHMRC (ID#339435), The Cancer Council Queensland (ID#4196615) and Cancer Council Tasmania (ID#403031 and ID#457636). SEARCH recruitment was funded by a program grant from Cancer Research UK (C490/A10124). The Bavarian Endometrial Cancer Study (BECS) was partly funded by the ELAN fund of the University of Erlangen. The Hannover-Jena Endometrial Cancer Study was partly supported by the Rudolf Bartling Foundation. The Leuven Endometrium Study (LES) was supported by the Verelst Foundation for endometrial cancer. The Mayo Endometrial Cancer Study (MECS) and Mayo controls (MAY) were supported by grants from the National Cancer Institute of United States Public Health Service (R01 CA122443, P30 CA15083, P50 CA136393, and GAME-ON the NCI Cancer Post-GWAS Initiative U19 CA148112), the Fred C and Katherine B Andersen Foundation, the Mayo Foundation and the Ovarian Cancer Research Fund with support of the Smith family, in memory of Kathryn Sladek Smith. MoMaTEC received financial support from a Helse Vest Grant, the University of Bergen, Melzer Foundation, The Norwegian Cancer Society (Harald Andersens legat), The Research Council of Norway and Haukeland University Hospital. The Newcastle Endometrial Cancer Study (NECS) acknowledges contributions from the University of Newcastle, The NBN Children's Cancer Research Group, Ms Jennie Thomas and the Hunter Medical Research Institute. RENDOCAS was supported through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet (numbers: 20110222, 20110483, 20110141 and DF 07015), The Swedish Labor Market Insurance (number 100069) and The Swedish Cancer Society (number 11 0439). The Cancer Hormone Replacement Epidemiology in Sweden Study (CAHRES, formerly called The Singapore and Swedish Breast/Endometrial Cancer Study; SASBAC) was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institutes of Health and the Susan G. Komen Breast Cancer Foundation.

The Nurses' Health Study (NHS) is supported by the NCI, NIH Grants Number UM1 CA186107, P01 CA087969, R01 CA49449, 1R01 CA134958 and 2R01 CA082838. The authors thank the participants and staff of the Nurses' Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. The authors also thank Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School. Finally, the authors also acknowledge Pati Soule and Hardeep Ranu for their laboratory assistance. The Connecticut Endometrial Cancer Study was supported by NCI, NIH Grant Number RO1CA98346. The Fred Hutchinson Cancer Research Center (FHCRC) is supported by NCI, NIH Grant Number NIH RO1 CA105212, RO1 CA 87538, RO1 CA75977, RO3 CA80636, NO1 HD23166, R35 CA39779, KO5 CA92002 and funds from the Fred Hutchinson Cancer Research Center. The Multiethnic Cohort Study (MEC)

is supported by the NCI, NHI Grants Number CA54281, CA128008 and 2R01 CA082838. The California Teachers Study (CTS) is supported by NCI, NIH Grant Number 2R01 CA082838, R01 CA91019 and R01 CA77398, and contract 97-10500 from the California Breast Cancer Research Fund. The Polish Endometrial Cancer Study (PECS) is supported by the Intramural Research Program of the NCI. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) is supported by the Extramural and the Intramural Research Programs of the NCI.

Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database.

Funding information

Australian National Health and Medical Research Council; VicHealth and Cancer Council Victoria; Fred Hutchinson Cancer Research Center; Susan G. Komen Breast Cancer Foundation; Agency for Science, Technology and Research of Singapore (A*STAR); The Swedish Cancer Society, Grant/Award Number: 11 0439; The Swedish Labor Market Insurance, Grant/Award Number: 100069; Stockholm County Council and Karolinska Institutet, Grant/Award Numbers: DF 07015, 20110141, 20110483, 20110222; Haukeland University Hospital; The Research Council of Norway; The Norwegian Cancer Society; Melzer Foundation; Helse Vest Grant; Mayo Foundation; Fred C and Katherine B Andersen Foundation; National Cancer Institute of United States Public Health Service, Grant/Award Numbers: P50 CA136393, P30 CA15083, R01 CA122443; Verelst Foundation; Rudolf Bartling Foundation; ELAN fund of the University of Erlangen; Cancer Council Tasmania, Grant/Award Numbers: ID#457636, ID#403031; The Cancer Council Queensland, Grant/Award Number: ID#4196615; National Cancer Institute, Grant/Award Number: U19 CA148065-01; US Department of Health and Human Services, Grant/Award Numbers: HHSN271201100004C, HHSN268201100004C, HHSN268201100003C, HHSN268201100002C, HHSN268201100001C, HHSN268201100046C; National Heart, Lung, and Blood Institute; Wellcome Trust Case Control Consortium (WTCCC), Grant/Award Numbers: 090532/Z/09Z, 085475, 068545/Z/02; NHMRC Senior Research Fellowship, Grant/Award Number: APP1061779; NHMRC Early Career Fellowship, Grant/Award Number: APP1111246; Australian Government Research Training Program PhD Scholarship and QIMR Berghofer Postgraduate Top-Up Scholarship, Grant/Award Numbers: 1074383, 396414, 209057; Cancer UK Grant, Grant/Award Number: C1287/A16563; NIH Grant, Grant/Award Numbers: R01 CA77398, R01 CA91019, 2R01 CA082838, CA128008, CA54281, KO5 CA92002, R35 CA39779, NO1 HD23166, RO3 CA80636, R01 CA75977, R01 CA 87538, R01 CA105212, 1R01 CA134958, R01 CA49449, P01 CA087969, UM1 CA186107, U19 CA148065; Genome Canada Grant, Grant/Award Number: GPH-129344; US National Institutes of Health, Grant/Award Numbers: R01-CA058598, R01-CA149429, U19-CA148112, CA1X01HG007491-01; Ovarian Cancer Research Fund; Breast Cancer Research Foundation; Canadian Institutes of Health Research (CIHR), Grant/Award Number: MOP-86727; US Department of Defence, Grant/Award Number: W81XWH-10-1-0341; Post-Cancer GWAS initiative, Grant/Award Numbers: 1U19 CA148112, 1U19 CA148065, 1U19 CA148537; the National Institutes of Health, Grant/Award Number: CA128978; Cancer Research UK, Grant/Award Numbers: C490/A10124, C8197/A16565, C5047/A10692, C5047/A15007, C5047/A8384, C1281/A12014, C12292/A11174, C1287/A10710, C1287/A10118; European Community's Seventh Framework Programme, Grant/Award Number: 223175; National Health and Medical Research Council (NHMRC), Grant/Award Numbers: ID#339435, G0000934, ID#1031333, ID#552402, ID#1109286

DATA AVAILABILITY STATEMENT

Only publicly available data were used in this study, and data sources and handling of these data are described in the Materials and Methods. Further details are available from the corresponding author upon request.

Abbreviations:

BMI	body mass index
CI	confidence interval
GSMR	Generalized Summary-data based Mendelian Randomization
GWAS	genome-wide association study
HDL	high-density lipoprotein

HEIDI	Heterogeneity in Dependent Instruments
LDL	low-density lipoprotein
OR	odds ratio

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68:394–424. [PubMed: 30207593]
2. Johnatty SE, Tan YY, Buchanan DD, et al. Family history of cancer predicts endometrial cancer risk independently of lynch syndrome: implications for genetic counselling. *Gynecol Oncol.* 2017;147:381–387. [PubMed: 28822557]
3. Webb PM. Environmental (nongenetic) factors in gynecological cancers: update and future perspectives. *Future Oncol.* 2015;11:295–307.
4. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. *Lancet.* 2016;387:1094–1108. [PubMed: 26354523]
5. Neale KT, Sharp SJ, Thompson DJ, et al. Evidence of a causal association between insulinemia and endometrial cancer: a Mendelian randomization analysis. *J Natl Cancer Inst.* 2015;107(9):djv178. 10.1093/jnci/djv178. [PubMed: 26134033]
6. Crosbie E, Morrison J. The emerging epidemic of endometrial cancer: time to take action. *Cochrane Database Syst Rev.* 2014 Issue 12 Art. No.: ED000095. 10.1002/14651858.ED000095.
7. Aune D, Navarro Rosenblatt DA, Chan DS, et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. *Ann Oncol.* 2015;26:1635–1648. [PubMed: 25791635]
8. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab.* 2004;89:2548–2556. [PubMed: 15181022]
9. Yang XL, Cui ZZ, Zhang H, et al. Causal link between lipid profile and bone mineral density: a Mendelian randomization study. *Bone.* 2019;127:37–43. [PubMed: 31158506]
10. Bakiri L, Hamacher R, Grana O, et al. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. *J Exp Med.* 2017;214:1387–1409. [PubMed: 28356389]
11. Rossin D, Calfapietra S, Sottero B, Poli G, Biasi F. HNE and cholesterol oxidation products in colorectal inflammation and carcinogenesis. *Free Radic Biol Med.* 2017;111:186–195. [PubMed: 28089726]
12. Du Q, Wang Q, Fan H, et al. Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome. *Biochem Pharmacol.* 2016;105:42–54. [PubMed: 26921636]
13. Hirasawa A, Makita K, Akahane T, et al. Hypertriglyceridemia is frequent in endometrial cancer survivors. *Jpn J Clin Oncol.* 2013;43:1087–1092. [PubMed: 23999769]
14. Swanson CA, Potischman N, Barrett RJ, et al. Endometrial cancer risk in relation to serum lipids and lipoprotein levels. *Cancer Epidemiol Biomark Prev.* 1994;3:575–581.
15. Zhang Y, Liu Z, Yu X, et al. The association between metabolic abnormality and endometrial cancer: a large case-control study in China. *Gynecol Oncol.* 2010;117:41–46. [PubMed: 20096921]
16. Friedenreich CM, Biel RK, Lau DC, et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. *Cancer Epidemiol Biomark Prev.* 2011;20:2384–2395.
17. Lindemann K, Vatten LJ, Ellstrom-Eng M, Eskiold A. Serum lipids and endometrial cancer risk: results from the HUNT-II study. *Int J Cancer.* 2009;124:2938–2941. [PubMed: 19267407]
18. Seth D, Garmo H, Wigertz A, et al. Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. *Int J Mol Epidemiol Genet.* 2012;3:122–133. [PubMed: 22724049]
19. Bjorge T, Stocks T, Lukanova A, et al. Metabolic syndrome and endometrial carcinoma. *Am J Epidemiol.* 2010;171:892–902. [PubMed: 20219764]

20. Kabat GC, Kim MY, Chlebowski RT, Vitolins MZ, Wassertheil-Smoller S, Rohan TE. Serum lipids and risk of obesity-related cancers in postmenopausal women. *Cancer Cause Control*. 2018;29:13–24.
21. Cust AE, Kaaks R, Friedenreich C, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Endocr Relat Cancer*. 2007;14:755–767. [PubMed: 17914105]
22. Fortner RT, Husing A, Kuhn T, et al. Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort. *Int J Cancer*. 2017;140:1317–1323. [PubMed: 27935083]
23. Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME, Brinton LA. Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database. *Cancer Epidemiol Biomark Prev*. 2015;24:261–267.
24. Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. *JAMA*. 2017;318:1925–1926. [PubMed: 29164242]
25. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013;45:1274–1283. [PubMed: 24097068]
26. O'Mara TA, Glubb DM, Amant F, et al. Identification of nine new susceptibility loci for endometrial cancer. *Nat Commun*. 2018;9:3166. [PubMed: 30093612]
27. Cheng TH, Thompson DJ, O'Mara TA, et al. Five endometrial cancer risk loci identified through genome-wide association analysis. *Nat Genet*. 2016;48:667–674. [PubMed: 27135401]
28. Zhu Z, Zheng Z, Zhang F. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat Commun*. 2018;9:224. [PubMed: 29335400]
29. Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic causal inference across the human phenome. *Elife*. 2018;7:e34408. [PubMed: 29846171]
30. Yengo L, Sidorenko J, Kempner KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry. *Hum Mol Genet*. 2018;27:3641–3649. [PubMed: 30124842]
31. Feingold KR, Grunfeld C. Introduction to lipids and lipoproteins In: De Groot LJ, Chrousos G, Dungan K, et al., eds. *Endotexted*. South Dartmouth, MA: Endotext; 2000.
32. Holmes MV, Lange LA, Palmer T, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. *Am J Hum Genet*. 2014;94:198–208. [PubMed: 24462370]
33. Painter JN, O'Mara TA, Marquart L, et al. Genetic risk score Mendelian randomization shows that obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer. *Cancer Epidemiol Biomark Prev*. 2016;25:1503–1510.
34. Laclaustra M, Lopez-Garcia E, Civeira F, et al. LDL cholesterol rises with BMI only in lean individuals: cross-sectional U.S. and Spanish representative data. *Diabetes Care*. 2018;41:2195–2201. [PubMed: 30061315]
35. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? *J Clin Oncol*. 2013;31:2607–2618. [PubMed: 23733771]
36. Yang HP, Wentzensen N, Trabert B, et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP diet and Health study. *Am J Epidemiol*. 2013;177:142–151. [PubMed: 23171881]
37. Nowak C, Arnlov J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk. *Nat Commun*. 2018;9:3957. [PubMed: 30262900]
38. Johnson KE, Klarin D, et al. Assessing a causal relationship between circulating lipids and breast cancer risk: Mendelian randomization study. *bioRxiv*. 2019 10.1101/794594.
39. Beeghly-Fadiel A, Khankari NK, Delahanty RJ, Shu XO, Lu Y, Schmidt MK, Bolla MK, Michailidou K, Wang Q, Dennis J, Yannoukakos D, Dunning AM, et al. A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. *Int J Epidemiol* 2019 10.1093/ije/dyz242.
40. Carreras-Torres R, Johansson M, Haycock PC, et al. Obesity, metabolic factors and risk of different histological types of lung cancer: a Mendelian randomization study. *PloS One*. 2017;12:e0177875. [PubMed: 28594918]

41. He L, Culminkaya I, Loika Y, et al. Causal effects of cardiovascular risk factors on onset of major age-related diseases: a time-to-event Mendelian randomization study. *Exp Gerontol.* 2018;107:74–86. [PubMed: 28964830]
42. Fossel ET, Zanella CL, Fletcher JG, Hui KK. Cell death induced by peroxidized low-density lipoprotein: endopepsis. *Cancer Res.* 1994;54:1240–1248. [PubMed: 8118812]
43. Jin F, Hagemann N, Brockmeier U, Schafer ST, Zechariah A, Hermann DM. LDL attenuates VEGF-induced angiogenesis via mechanisms involving VEGFR2 internalization and degradation following endosome-trans-Golgi network trafficking. *Angiogenesis.* 2013;16:625–637. [PubMed: 23429999]
44. Osto E, Matter CM, Kouroedov A, et al. c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. *Circulation.* 2008;118:2073–2080. [PubMed: 18955669]
45. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature.* 2004;431:461–466. [PubMed: 15329734]
46. Pan B, Ren H, He Y, et al. HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. *Clin Cancer Res.* 2012;18:1246–1256. [PubMed: 22261802]

What's new?

Some studies have suggested that serum lipids may correlate with endometrial cancer (EC) risk, but results have been inconsistent. In our study, the authors used genetic markers to predict LDL and HDL cholesterol levels and analyze EC risk. They found that when lower LDL or higher HDL levels were predicted, EC risk was increased. These results support a role for LDL and HDL cholesterol in the development of EC, and lipid levels may represent a risk factor for EC. Further studies are required to assess the biological and clinical significance of these associations.

FIGURE 1.

Effects of blood lipid trait instrumental variables on endometrial cancer risk. Figure showed the Generalized Summary-data based Mendelian Randomization (GSMR) results for (A) low-density lipoprotein (LDL)-endometrial cancer (all histologies combined), (B) LDL-endometrioid histology, (C) LDL-non-endometrioid histologies, (D) high-density lipoprotein (HDL)-endometrial cancer (all histologies combined), (E) HDL-endometrioid histology, (F) HDL-non-endometrioid histology, (G) triglycerides-endometrial cancer (all histologies combined), (H) Triglycerides-endometrioid histology and (I) triglycerides-non-endometrioid histologies. The effect of each genetic variant for lipid of interest is plotted against the effect for the same variant on endometrial cancer risk. Dashed lines represent GSMR estimates

FIGURE 2. Relationships between low-density lipoprotein (LDL) cholesterol, body mass index (BMI) and endometrioid endometrial cancer identified by previous^{4,26} and current Mendelian randomization analysis. Red lines represent adverse effects, and green lines represent protective effects

TABLE 1

Results from Generalized Summary-data based Mendelian Randomization (GSMR) analysis from blood lipid levels to endometrial cancer risk

Blood lipid levels	All histologies (12 906 cases and 108 979 controls)				Endometrioid histology (8758 cases and 46 126 controls)				Non-endometrioid histology (1230 cases and 35 447 controls)			
	SNPs (N)	OR (95% CI)	P	Outliers removed by HEIDI test	SNPs (N)	OR (95% CI)	P	Outliers removed by HEIDI test	SNPs (N)	OR (95% CI)	P	Outliers removed by HEIDI test
LDL cholesterol, SD	140	0.88 (0.83-0.93)	7.26E-06	rs579459, rs7832643, rs11679386, rs3798167, rs11065987, rs1250229	142	0.89 (0.83-0.95)	5.37E-04	rs579459, rs3798167, rs3798180, rs11065987	145	0.76 (0.65-0.89)	6.18E-04	rs1475701
HDL cholesterol, SD	163	1.07 (1.00-1.14)	.037	rs653178, rs1980493, rs1121980	161	1.03 (0.95-1.11)	.506	rs653178, rs1980493, rs74458891, rs1121980, rs4983559	166	1.22 (1.01-1.47)	.036	Nil
Triglycerides, SD	104	0.96 (0.89-1.04)	.337	rs2075650, rs2442719	106	0.95 (0.86-1.05)	.312	Nil	104	1.10 (0.87-1.39)	.424	rs61905084, rs2075650

Note: Results passing Bonferroni correction ($P < .017$) are in bold. Effect estimate represents the endometrial cancer risk per 1 SD increment in assessed blood lipid level.

Results from Generalized Summary-data based Mendelian Randomization (GSMR) analysis from liability to endometrial cancer to blood lipid levels

Abbreviation: Beta, SD change for assessed blood lipid level per SD increase in the liability to endometrial cancer.

TABLE 3

Results from Generalized Summary-data based Mendelian Randomization (GSMR) analysis from blood lipid levels to endometrial cancer risk, after conditioning on body mass index (BMI)

	All histologies (12 906 cases and 108 979 controls)				Endometrioid histology (8758 cases and 46 126 controls)				Non-endometrioid histology (1230 cases and 35 447 controls)			
	SNPs (N)	OR (95% CI)	P	Outliers removed by HEIDI test	SNPs (N)	OR (95% CI)	P	Outliers removed by HEIDI test	SNPs (N)	OR (95% CI)	P	Outliers removed by HEIDI test
Blood lipid levels												
LDL cholesterol, SD	141	0.90 (0.85-0.96)	1.36E-03	rs579459, rs11679386, rs3798167, rs11065987	142	0.93 (0.87-1.01)	.071	rs3798167, rs3798180, rs11065987	144	0.76 (0.63-0.90)	2.13E-03	rs1475701
HDL cholesterol, SD	168	1.06 (0.99-1.13)	.083	rs653178	168	1.02 (0.95-1.10)	.589	rs653178	169	1.20 (1.00-1.45)	.048	Nil
Triglycerides, SD	114	0.98 (0.90-1.06)	.608	rs2075650, rs2528707, rs17401675	115	0.96 (0.87-1.05)	.365	rs13133548, rs17401675	116	1.15 (0.90-1.45)	.258	rs2075650

Note: Results passing Bonferroni correction ($P < .017$) are in bold. Effect estimate represents the endometrial cancer risk per 1 SD increment in assessed blood lipid level.